Targeted immunotherapy as an evolving strategy for the
treatment of primary, residual and metastatic cancer.
Despite the appearance of a number of monoclonal
antibodies in advanced stages of development, this
therapeutic strategy has yet to live up to early
promise. A recent area in which immunotherapy has been
exploited is that of targeted immunotherapy. This
involves the targeting of toxins or isotopes to
cancerous cells. Despite early limitations this
therapeutic area is beginning to achieve results
particularly with respect to leukemia and lymphoma,
although solid tumors may still benefit. A dossier has
been produced that:
> Analyzes the limitations of early antibody
therapies and charts the development of high affinity
antibodies into the cornerstones of today's
radioimmunotherapies and immunoconjugates
> Overviews the gradual optimization of the
various components of targeted immunotherapy
> Provides an overview of the successes and
limitations associated with these therapies
> Profiles radioimmunotherapies and
immunoconjugates in advanced development
> Offers key statistics concerning types of cancer
most commonly targeted by immunotherapies
> Identifies academic labs that could help
expedite screening or provide biological material (such
as human material) to fully characterize the clinical
potential of novel immunotherapeutics.
Price: $100.00 Order
here!
